Home » TMP/SMX » Page 2

Tag Archives: TMP/SMX

Sulfonamides Revisited, With an Emphasis on Dapsone

Posted on by — No Comments ↓

The sulfonamide moiety is a remarkable structure giving rise to diverse drugs in arious therapeutic areas such as antibiotics, antidiabetics, diuretics and anti-inflammatory agents. In regards to antibiotics, sulfonamides are in common use as antifungals (P. jiroveci), antiparasitics (toxoplasmosis, cyclospora, isospora, malaria) antibacterials (including against nocardia and certain ones causing STDs) Continue reading Sulfonamides Revisited, With an Emphasis on Dapsone→

The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?

Posted on by — No Comments ↓

Any FDA meeting is a high-stakes game for industry:  One never knows how the discussions will go. Some oddball issue may take center stage and usurp much time, creating an unbalanced perspective.  At other times, simple issues seem to create controversy, questions are not properly understood in the context of Continue reading The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?→

Nitrofurantoin – An Old Drug Resurrected Needs Prospective Scrutiny

Posted on by — No Comments ↓

When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited data, often considered incomplete by today’s standards.  Take colistin as an example: approved in the early 60ies, we still Continue reading Nitrofurantoin – An Old Drug Resurrected Needs Prospective Scrutiny→